The long-term behavior of endothelial markers was studied in patients with Eisenmenger syndrome who were subjected to conventional therapy (no vasodilators) and observed for 18 months. Biochemical markers were analyzed comparatively in patients with class II or III symptoms (group 1, n=10) and patients with class IV symptoms (group 2, n=7). Plasma von Willebrand factor antigen (vWF:Ag), thrombomodulin, tissue-type plasminogen activator (t-PA) and its inhibitor (PAI-1), and D-dimer were determined by immunoenzymatic assay at baseline, and at 6, 12, and 18 months. At baseline, the main clinical difference between groups was a decreased peripheral oxygen saturation in group 2 versus group 1 (77±5% and 86±4%, respectively, p=0.001). Basal vWF:Ag and t-PA were increased and thrombomodulin was decreased in both groups in comparison with controls (p<0.0001), while D-dimer was increased in group 2 only (p=0.0003). In response to treatment, there was a decrease in vWF:Ag in both groups (19% and 23%, respectively in groups 1 and 2, at 18 months vs. baseline, p<0.0001) and t-PA in group 1 (38% vs. baseline, p=0.0485). Plasma vWF:Ag tended to be higher in group 2 in comparison with group 1 during the whole follow-up. Levels of PAI-1 greater than 38.4 ng/mL (upper 90% limit for normals) and D-dimer greater than 500 ng/mL were detected in individual patients (both groups) during the follow-up period. Thrombomodulin remained decreased in both groups. Thus, severity of symptoms in the Eisenmenger syndrome appears to correlate with low oxygen saturation and higher vWF:Ag levels. Improvement of endothelial dysfunction may occur in response to treatment, although increased risk for thrombosis persists, in view of residual abnormalities.
The Eisenmenger syndrome may be defined as advanced pulmonary arterial hypertension secondary to congenital heart defects with reverse shunting across intracardiac lesions, resulting in systemic oxygen desaturation and erythrocytosis. Chronic hypoxemia and blood hyperviscosity due to erythrocytosis may shift the endothelial behavior toward a procoagulant state, resulting in increased risk of pulmonary and systemic thrombotic events (1, 2) . Proximal pulmonary arterial and intrapulmonary thrombosis have been re-ported (3, 4) . In a recent study of ours, pulmonary arterial thrombosis was observed in 35% of patients with Eisenmenger syndrome as an age-dependent complication (5) .
Although previous studies have demonstrated abnormal endothelial function and altered coagulation and fibrinolysis in patients with pulmonary hypertension (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) , there are few reports focusing on endothelial dysfunction and intravascular coagulation in the particular setting of the Eisenmenger syndrome. Decreased plasma thrombomodulin has been observed in these patients, suggestive of decreased availability of this anticoagulant proteoglycan on the surface of endothelial cells (5, 16) .
In primary pulmonary hypertension, the chronic behavior of the endothelium and platelets in response to prostacyclin administration has been investigated with significant improvement of pretreatment abnormalities (17) .
In the Eisenmenger syndrome, conventional medical therapy is focused primarily on avoiding complications (1) . In contrast to primary pulmonary hypertension however, the long-term behavior of endothelial and coagulation markers has not been investigated. In the analysis of endothelial dysfunction markers, a considerable variability of results may be observed when plasma levels are determined once per patient. We therefore planned the present study to analyze the long-term behavior of endothelial and coagulation markers in patients with Eisenmenger syndrome who were subjected to conventional therapy and observed for 18 months. Four determinations were performed per patient during the study period. We also attempted to correlate the behavior of biochemical markers with the severity of the disease looking at different patient subgroups in terms of clinical presentation.
METHODS

Patient Population
From January 2001 to June 2002, 19 patients with congenital heart disease and the Eisenmenger reaction were admitted to the Heart Institute, São Paulo, Brazil, for diagnosis and treatment. Two of these 19 consecutive patients died of advanced disease 3 and 12 months after admittance and were not included in this study. The remaining 17 patients were observed for 18 months under medical treatment up to December 2003 and represented our patient population. The Eisenmenger syndrome was defined as advanced pulmonary hypertension with reversal shunting across intracardiac lesions resulting in progressive peripheral oxygen desaturation and erythrocytosis. Thus, all patients were considered unsuitable for surgical correction of the cardiac defects. No other forms of pulmonary hypertension were included. Patients (or their parents in case of children and adolescents) gave an informed consent for inclusion and the study protocol was approved by the Scientific and Ethics Committee of the Heart Institute.
Patient Subgroups
After inclusion, patients were classified as group 1 or group 2 based on the severity of clinical presentation. Patients with stable clinical conditions, presenting with class II or class III symptoms (New York Heart Association, NYHA) were classified as group 1. Those with unstable disease and recent episodes of clinical worsening in their history, requiring emergency assistance (class III alternating with class IV symptoms) were classified as group 2. Most such episodes included at least one of the following events: worsening of dyspnea and cyanosis, chest pain with or without hemoptysis, edema, or neurologic manifestations suggestive of transient brain ischemia.
Medical Treatment and Study Design
Having met the criteria for inclusion, patients were subjected to medical treatment, which included five specific measures: 1) anticoagulation with warfarin at appropriate doses to maintain an international normalized ratio between 2.0 and 2.5; 2) chronic oxygen administration on an outpatient basis (8 to 10 hours a day); 3) isovolemic hemodilution as previously described (18) , only in the presence of hyperviscosity-related symptoms; 4) iron administration (oral route) when necessary to replenish stores and prevent microcytosis; and 5) cautious administration of diuretics when absolutely necessary. No vasodilators were administered to any patients. Routine medical evaluation and general laboratory tests were performed every 3 months. Specific determinations of endothelial and coagulation markers were performed at baseline and every 6 months thereafter, until completion of 18 months. Specific laboratory tests were always performed in patients in steady conditions, never during emergency care.
General Laboratory Tests
General determinations included peripheral oxygen saturation (pulse oximetry) and hematocrit. Intracardiac defects were analyzed with two-dimensional echocardiography with color flow Doppler imaging. The mean pulmonary arterial pressure was determined the same way, using data obtained from the curve of pulmonary regurgitation. Patients with more complex defects were subjected to complete cardiac catheterization. However, comparison of hemodynamics between patient groups was performed using noninvasive estimation of pulmonary artery pressure, which was available in all patients. As an attempt to investigate the possible occurrence of pulmonary arterial thrombosis, a common complication in the Eisenmenger syndrome, all patients were subjected to computed tomography (CT) and pulmonary CT angiography.
Endothelial Dysfunction and Intravascular Coagulation Markers
Peripheral venous blood was collected without tourniquet in 1:10 volumes of 3.8% sodium citrate and subjected to centrifugation at 3000g for 20 minutes. Plasma was separated, aliquoted, and stored at -80°C until use. Control plasma was obtained from 20 healthy volunteers with an age range similar to that of patients.
We measured the plasma levels of tissue-type plasminogen activator (t-PA), plasminogen activator inhibitor (PAI-1), thrombomodulin and von Willebrand factor antigen (vWF:Ag) as indexes of endothelial activation/dysfunction, and Ddimer as a marker of intravascular coagulation followed by fibrinolysis. All determinations were performed by enzyme-linked immunosorbent assays (ELISA) using kits from Diagnostica Stago, Asniéres, France. Results were obtained by comparison with a standard curve with reagents provided by the manufacturer. Patient and control samples were always run in parallel in the same assay.
Statistical Analysis
All variables under investigation were tested for closeness to the normal (Gaussian) distribution before decision about using parametric or nonparametric statistics. Results are expressed as mean±SD or median and range. D-dimer was tested nonparametrically first and then parametrically after logarithmic transformation. Comparisons between two groups (patients vs. controls) were performed using the student t test or the Mann-Whitney test for numeric variables and Fisher's exact test for categorical variables. Comparisons involving three groups (controls, patient group 1 and group 2) were performed using analysis of variance (ANOVA) or Friedman's statistics, followed by appropriate multicomparison tests. Differences between and within subjects during the follow-up were tested using unbalanced two-factor (patient group and time) ANOVA with repeated measures of one factor (time). In all tests a significance level of 0.05 was assumed. Data analysis was carried out using the SPSS statistical software (version 10.0, Chicago, IL, USA).
RESULTS
Individual diagnostic data of 17 patients with Eisenmenger syndrome (9 women) are depicted in Table 1 . Age range was 4 to 52 years (median, 34 years). Patients had mean pulmonary artery pressure of 56 ± 17 mmHg, peripheral oxygen saturation of 83 ± 6% and hematocrit of 59 ± 5%. Ten patients had stable clinical conditions with class II or III symptoms and were classified as group 1. Seven patients had class III/IV symptoms with recent episodes of clinical worsening requiring emergency care and were classified as group 2.
Patient groups as defined by clinical presentation differed in terms of peripheral oxygen saturation, with lower values in group 2 (p=0.001) ( Table 2 ). Of notice, age, mean pulmonary artery pressure, and the hematocrit were very similar. Although the incidence of pulmonary arterial thrombosis was higher in group 2 ( Fig. 1) , the difference was not significant.
At baseline, plasma levels of vWF:Ag, and t-PA were significantly increased and thrombomodulin was decreased in both groups in comparison with controls (p<0.0001 for all variables), while D-dimer was increased in group 2 only (p=0.0003) ( Table 3 ). Significant differences between groups were detected for vWF:Ag and D-dimer (p<0.05). Baseline PAI-1 was within the normal range in both groups.
During the follow-up, no patients had any relevant bleeding episodes as a consequence of anticoagulant therapy or adverse effects of hemodilution procedures. In spite of treatment, patients in group 2 still had periods of class IV symptoms during the follow-up, thus requiring hospital care. Consequently, although some level of clinical improvement was achieved in most patients as a result of medical treatment, all patients remained in their original group throughout the follow-up.
In response to treatment, a significant decrease in plasma levels of vWF:Ag (p<0.0001) and t-PA (p=0.0414) was observed. Also, a decrease in the variability of t-PA values was observed at 12 and 18 months in comparison with baseline and 6 months of follow-up (Fig. 2 ). While vWF:Ag decreased in both patient groups (p<0.0001) with a trend toward higher values in group 2 (p=0.0569), t-PA decreased significantly in group 1 only (p=0.0485) (Fig. 2) . The median values of D-dimer did not change, but high levels were observed in individual patients in both groups. Although the average levels of PAI-1 did not change significantly, high levels were detected in three patients during the follow-up (Fig. 2) . The high levels of PAI-1 observed at 12 months (70.6, 44.0, and 49.5 ng/mL, respectively in patients 7, 8, and 11) were associated with low D-dimer levels (210, 56, and 92 ng/mL, respectively), suggesting impaired fibrinolysis. In patient 7, plasma PAI-1 was 60.9 ng/mL at 18 months, with a PAI-1/t-PA ratio of 4.8 (average normal ratio, 2.9). The upper tolerance limit for PAI-1 in our controls was 38.4 ng/mL (>95% confidence). Plasma thrombomodulin remained at low levels in both patient groups.
DISCUSSION
In this study, we showed that patients with Eisenmenger syndrome in the same age range and with comparable levels of pulmonary artery pressure may present with considerable differences in terms of symptoms and stability of the clinical course associated with differences in the severity of endothelial and coagulation abnor- malities as suggested by plasma levels of biochemical markers. We observed that patients with unstable disease (group 2) were more hypoxemic and had higher circulating levels of Ddimer and vWF:Ag in comparison with those with a more stable clinical condition (group 1). Although it seems attractive to speculate that patients with an unstable clinical course have a higher incidence of pulmonary arterial thrombosis, based on the ratio of 4 to 7 in our group 2 in comparison with the ratio of 2 to 10 in group 1, further observations involving a larger patient population are required to demonstrate this association. We also demonstrated that improvement of clinical and laboratory abnormalities may be expected following conventional medical therapy. In our patients, however, the improvement was limited and not observed for all variables under investigation. In this way, a differential behavior was observed in group 1 in comparison with group 2, with a consistent and significant decrease in plasma t-PA in the former group, associated with a progressive decrease in vWF:Ag approaching the normal levels at 18 months. Changes in plasma levels of endothelial and coagulation markers observed in our patients are likely related to the pathophysiologic mechanisms known to be present in the Eisenmenger syndrome. von Willebrand factor and t-PA are localized to endothelial Weibel-Palade bodies (19) and are easily released from endothelial cells by a number of secretagogues (20) . In our patients, decreased oxygen saturation may have accounted at least in part for heightened plasma levels of these proteins, because hypoxia has been shown to induce exocytosis of Weibel-Palade bodies (21) . Furthermore, both t-PA mRNA and enzyme activity are induced by vascular endothelial growth factor (22) , also known to be transcriptionally upregulated under hypoxic conditions (23) . However, in hypoxemic patients with Eisenmenger syndrome, the relative contribution of pulmonary and systemic endothelial cells to the circulating levels of von Willebrand factor and t-PA is not known at present. In spite of the mentioned colocalization of von Willebrand factor and t-PA in Weibel-Palade bodies and the response of these cytoplasmic vesicles to hypoxia, the long-term analysis of these proteins in the present study showed that plasma vWF:Ag was more differentially displayed between group 1 and group 2 patients (e.g., less hypoxemic vs. more hypoxemic subjects) than was circulating t-PA (Fig. 2) . In this way, factors other than hypoxia may have influenced the plasma levels of vWF:Ag and t-PA since their reduction over time occurred in the absence of any relevant changes in oxygen saturation (not shown).
Endothelial cell membrane-associated thrombomodulin is a proteoglycan that binds and allows thrombin to activate protein C and thrombin-activatable fibrinolysis inhibitor, thus playing an important role in the control of coagulation and fibrinolysis (24) . In contrast to von Willebrand factor and t-PA, thrombomodulin is hardly leaked in the absence of endothelial injury. Heightened plasma levels of this molecule are generally associated with damage to endothelial cell membrane (25) . Plasma soluble thrombomodulin represents cleaved products of the membrane-associated proteoglycan. In this way, its concentration is assumed to reflect the level of synthesis by endothelial cells. Plasma thrombomodulin is an independent risk factor for coronary artery disease, with higher levels being considered protective (26) . Its expression is suppressed by proinflammatory cytokines, endotoxin, and shear stress (24) . In the Eisenmenger syndrome, impaired endothelial synthesis of thrombomodulin as suggested by decreased circulating levels may be in part due to low oxygen saturation because hypoxia has been shown to suppress thrombomodulin mRNA and the generation of activated protein C in endothelial cells (27) . In this study, the low plasma levels of thrombomodulin in group 1, in the same range as group 2, suggests that mild-to-moderate oxygen desaturation may be sufficient for inhibiting its synthesis. Unlike von Willebrand factor and t-PA, plasma thrombomodulin remained decreased over the follow-up in both groups, possibly reflecting a closer dependence on oxygen tension. This could be associated with a persistent risk of thrombolic events, in spite of anticoagulant therapy.
Results of plasma PAI-1 measurements in pulmonary hypertensive subjects may vary depending on the method used for its determination. Increased antigenic concentration has been reported (8) , while baseline activity of PAI-1 has been shown to be normal in these patients (7, 8) .
In spite of previous observation of hypoxia-induced transcription of the PAI-1 gene in vascular endothelial cells (28) , we failed to demonstrate any significant differences in baseline PAI-1 between the study groups and controls. A major limitation of our study, however, was that we did not measure PAI-1 and t-PA activities comparatively before and after venous occlusion. In pulmonary hypertension, the physiologic mechanism of decrease in PAI-1 activity in response to venous occlusion has been shown to be defective in comparison with healthy controls (7, 8) . In spite of our limitation, we were able to demonstrate high antigenic PAI-1 levels in three patients during the follow-up period. This suggests that repeated measurements of PAI-1 may be necessary in some cases to demonstrate its overexpression by endothelial cells. We speculate that the low D-dimer levels observed in association with heightened PAI-1 in these patients are more likely indicative of impaired fibrinolysis than absent intravascular coagulation.
The impact of anticoagulation on the outcome of patients with idiopathic pulmonary hypertension has been well demonstrated (29) . Nevertheless, the use of anticoagulants in the Eisenmenger syndrome is controversial because hemostatic abnormalities may occur, resulting in increased risk for bleeding episodes (1). In contrast to this concept is the observation of a high incidence of thrombosis, in particular in proximal pulmonary arteries (3) (4) (5) . The incidence of in situ pulmonary arterial thrombosis may be even higher if one considers the more distal pulmonary vessels, not depicted by conventional pulmonary CT angiography (30, 31) . In this study, at baseline, we observed a significant increase in D-dimer levels in group 2 in comparison with controls and group 1, associated with a higher (although not significant) incidence of pulmonary arterial thrombosis. Furthermore, high D-dimer levels were observed in patients from both groups during the follow-up period despite the use of warfarin. Because D-dimer is a split product of fibrin, normal levels may reflect defective fibrinolysis in some cases, rather than absence of intravascular coagulation. This is likely to have occurred in three patients, for whom exceedingly high PAI-1 levels were demonstrated. Thus, it does not seem reasonable to look at D-dimer level as a guide for starting anticoagulation in these patients. On the other hand, the long-term benefits of anticoagulation with warfarin remain to be demonstrated. Additional points that need to be addressed are the patient age at which anticoagulation should be started, the effectiveness of warfarin in preventing the progression of ongoing pulmonary arterial thrombosis, and alternative drugs to be used in this setting.
In summary, our patients with Eisenmenger syndrome had differences in clinical presentation that were related to the severity of hypoxemia, not age or pulmonary artery pressure. Patients at distinct clinical categories had different patterns of endothelial and coagulation abnormalities and a different behavior in terms of biochemical markers in response to long-term conventional therapy. This emphasizes the need for repeated measurements of biochemical markers in individual patients over time. Treatment was followed by partial improvement of biochemical abnormalities with a better response in subjects with a less severe disease. Persistently high Ddimer levels, in particular in the presence of angiographically demonstrated pulmonary arterial thrombosis points toward the need for anticoagulation in these patients, despite the risk for bleeding episodes. Nevertheless, our observations suggest that warfarin alone may not be protective in some patients on a long-term basis, thus emphasizing the need for development of new and more specific anticoagulant drugs.
